The Claim
In a modeled population of overweight or obese adults with preexisting cardiovascular disease and no diabetes, semaglutide 2.4 mg administered weekly may increase quality-adjusted life expectancy at an incremental cost of $72,962 per quality-adjusted life year (QALY) gained compared to standard care, based on a simulation model incorporating clinical trial data and economic assumptions.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people who are overweight or obese, have heart disease but not diabetes, taking a weekly semaglutide shot might help them live healthier, longer lives — and it would cost about $73,000 for each extra year of good-quality life, according to computer modeling.
See the scientific wording
In a modeled population of overweight or obese adults with preexisting cardiovascular disease and no diabetes, semaglutide 2.4 mg weekly may improve quality-adjusted life expectancy at an incremental cost of $72,962 per quality-adjusted life year (QALY) gained compared to standard care, based on a simulation using clinical trial data and economic assumptions.
What the research says
1 studyStudy: Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.
The study looked at the same drug, dose, and type of patients as the claim, and found the same cost per year of healthy life gained. So, it supports the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.